Pamidronate 40391-99-9 GlpBio

www.glpbio.com

Product Data Sheet

Product Name:Cat. No.:

PamidronateGC11115

Chemical Properties

Cas No.ChemicalNameCanonicalSMILESFormulaSolubilityGeneral tipsShippingCondition

40391-99-9

(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acidC(CN)C(O)(P(=O)(O)O)P(=O)(O)OC3H11NO7P2

≥2.35mg/mL in H2O with gentlewarming, <2.35mg/mL in DMSO

M.WtStorage

235.07Store at -20°C

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bathfor a while.Stock solution can be stored below -20℃ for several months.

Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice uponrequest.

Structure

Background

Caution: Producthasnot been fully validated for medical applications. For research use only.

Tel: (626) 353-8530 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

1www.glpbio.com

Peptides, Inhibitors, Agonists

www.glpbio.com

Product Data Sheet

Pamidronic acid is a drug used to treat a broad spectrum of bone absorption diseases.

Osteosarcoma cell viability decreases significantly in a concentration- and time-dependent manner at pamidronateconcentrations ranging from 100 to 1000 μM, most consistently after 48 and 72 hours' exposure. In treatedosteosarcoma cells, the lowest percentage cell viability is 34% (detected after 72 hours' exposure to 1000μMpamidronate)[1]. Pamidronate disodium inhibits Wnt and β-catenin signaling, which controls osteogenic

differentiation in BMMSCs. Wnt3a, a Wnt and β-catenin signaling activator, reverses the negative effects caused bypamidronate disodium to salvage the osteogenic defect in BMMSCs[2].

Pamidronic acid can significantly inhibit and even reverse early osteoarthritic subchondral bone loss, thus alleviatingthe process of cartilaginous degeneration. The mechanisms involved may be associated with the upregulation ofOPG expression, and downregulation of RANKL, MMP-9 and TLR-4 expression[3].

Reference:

[1]. Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcomacellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-91.

[2]. Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in HumanBone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 22.

[3]. Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression ofcartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:370.

Caution: Producthasnot been fully validated for medical applications. For research use only.

Tel: (626) 353-8530 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

2www.glpbio.com